Drug Trial Radar · NCT04165096
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)
Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
128
Actual
Start
Jan 21, 2020
Primary completion
Apr 30, 2025
Study completion May 28, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with boserolimab (MK-5890), MK-4830, MK-0482 in participants with advanced squamous or non-squamous NSCLC that have been previously treated with anti-PD-L1 therapy. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
PembrolizumabBiological
IV infusion
BoserolimabBiological
IV infusion
MK-4830Biological
IV infusion
diphenhydramineDrug
PO
acetaminophenDrug
PO
MK-0482Biological
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Time frame: Up to approximately 53 months
Locations
39 sites in 7 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center ( Site 0001)
Gilbert, Arizona
City of Hope ( Site 0014)
Duarte, California
UCSF Medical Center at Mission Bay ( Site 0007)
San Francisco, California
Georgetown University ( Site 0036)
Washington D.C., District of Columbia
University of Kentucky Markey Cancer Center ( Site 0019)
Lexington, Kentucky
MedStar Franklin Square Medical Center ( Site 0033)
Baltimore, Maryland
Massachusetts General Hospital ( Site 0003)
Boston, Massachusetts
Dana Farber Cancer Institute ( Site 0002)
Boston, Massachusetts
Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031)
Omaha, Nebraska
Dartmouth Hitchcock Medical Center ( Site 0016)
Lebanon, New Hampshire
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037)
Hackensack, New Jersey
Laura and Isaac Perlmutter Cancer Center ( Site 0034)
New York, New York
Sanford Fargo Medical Center ( Site 0039)
Fargo, North Dakota
Cleveland Clinic Main ( Site 0006)
Cleveland, Ohio
Ohio State University Comprehensive Cancer Center ( Site 0015)
Columbus, Ohio
Abramson Cancer Center of the University of Pennsylvania ( Site 0010)
Philadelphia, Pennsylvania
Sanford Cancer Center ( Site 0038)
Sioux Falls, South Dakota
The University of Texas MD Anderson Cancer Center ( Site 0009)
Houston, Texas
Orszagos Koranyi Pulmonologiai Intezet ( Site 0060)
Budapest, Hungary
Petz Aladar Megyei Oktato Korhaz ( Site 0062)
Győr, Győr-Moson-Sopron, Hungary
Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 0061)
Szolnok, Jász-Nagykun-Szolnok, Hungary
Soroka Medical Center ( Site 0072)
Beersheba, Israel
Rambam Health Care Campus-Oncology ( Site 0076)
Haifa, Israel
Shaare Zedek Medical Center ( Site 0075)
Jerusalem, Israel
Meir Medical Center ( Site 0071)
Kfar Saba, Israel
Rabin Medical Center ( Site 0074)
Petah Tikva, Israel
Chaim Sheba Medical Center ( Site 0070)
Ramat Gan, Israel
Sourasky Medical Center ( Site 0077)
Tel Aviv, Israel
IRCCS Ospedale San Raffaele ( Site 0171)
Milan, Italy
Azienda Ospedaliera Universitaria Careggi ( Site 0173)
Florence, Firenze, Italy
Policlinico Gemelli di Roma ( Site 0174)
Rome, Lazio, Italy
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier
Warsaw, Masovian Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)
Gdansk, Pomeranian Voivodeship, Poland
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0152)
Koszalin, West Pomeranian Voivodeship, Poland
Severance Hospital ( Site 0080)
Seoul, South Korea
Samsung Medical Center ( Site 0082)
Seoul, South Korea
Seoul National University Bundang Hospital ( Site 0081)
Seongnam-si, Kyonggi-do, South Korea
ICO L Hospitalet ( Site 0090)
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario Quiron Madrid ( Site 0091)
Pozuelo de Alarcón, Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.